Breathe Well Live Well
|
AEROCRINE AB : Aerocrine: First Primary Care Trial Supports FeNO-Guided …
4-traders (press release) Aerocrine AB (STO:AERO-B) – A new randomised clinical trial shows lower incidence of asthma exacerbations and increased asthma control with Fractional exhaled Nitric Oxide (FeNO)-guided anti-inflammatory treatment. The study has been published on … |
View full post on asthma – Google News
|
Aerocrine: UK clinical study demonstrates that asthma tests can identify non …
Business Wire (press release) SOLNA, Sweden–(BUSINESS WIRE)–Aerocrine AB (OMX Nordic Exchange: AERO) announces that a clinical trial published in The American Journal of Respiratory and Critical Care Medicine shows that FeNO-testing is an excellent tool to identify patients … |
View full post on asthma – Google News
|
Aerocrine: UK clinical study demonstrates that asthma tests can identify non …
The Herald | HeraldOnline.com SOLNA, Sweden — Aerocrine AB (OMX Nordic Exchange: AERO) announces that a clinical trial published in The American Journal of Respiratory and Critical Care Medicine shows that FeNO-testing is an excellent tool to identify patients that don't adhere to … |
View full post on asthma – Google News
|
Aerocrine: UK clinical study demonstrates that asthma tests can identify non …
Fort Mills Times Aerocrine AB (OMX Nordic Exchange: AERO) announces that a clinical trial published in The American Journal of Respiratory and Critical Care Medicine shows that FeNO-testing is an excellent tool to identify patients that don't adhere to treatment. |
View full post on asthma – Google News
|
Aerocrine: Positive reimbursement coverage continues for Aerocrine's asthma test
The Herald | HeraldOnline.com Specifically, FeNO testing is covered for the treatment of asthma when it is used in the diagnosis of allergic airway inflammation or when used in determining likelihood of steroid responsiveness in individuals with chronic symptoms suggestive of … |
View full post on asthma – Google News
|
Aerocrine: Aerocrine signs distribution agreement with third largest chinese …
The Herald | HeraldOnline.com The agreement, effective as of September 24, 2012, gives SPH exclusive rights for import and non-exclusive rights for distribution of Aerocrine's instrument NIOX MINO® and test kits, used for diagnosing and monitoring patients with asthma, on the … |
View full post on asthma – Google News
|
Aerocrine: BlueCross BlueShield of Minnesota to begin FeNO Coverage in August
Business Wire (press release) Following the transition period, exhaled nitric oxide measurement (CPT code 95012) will be covered for patients with asthma. BlueCross BlueShield of Minnesota is the largest insurance company in the state and provides coverage to approximately 66 … |
View full post on asthma – Google News
|
Aerocrine: BlueCross BlueShield of Florida Continues Trend, Retires Negative …
Business Wire (press release) We will be better able to identify patients who will respond to inhaled corticosteroids and even determine in whom we may be able to decrease the doses of asthma controller medications” Aerocrine AB (NASDAQ OMX NORDIC: AERO)(STO:AEROB) announces that … |
View full post on asthma – Google News
|
Aerocrine: South Carolina Adopts Positive Coverage of Aerocrine's FeNo Testing …
Business Wire (press release) “FeNO testing is a significant advancement in managing the patient with asthma. Since the publication of the American Thoracic Guideline on FeNO, this test should be standard of care in every clinic managing asthma patients. South Carolina adopts positive coverage of Aerocrine's FeNO testing in … |
View full post on asthma – Google News
|
Aerocrine appoints Morten Gunvad as VP Commercial Operations Europe and Asia
CisionWire (press release) I am excited to join Aerocrine and contribute to making the company's products available to a growing number of patients living with asthma.” “Aerocrine is commercially active in numerous European and Asian markets where a significant share of the … |
View full post on asthma – Google News